Evommune: Early-Stage Pipeline, Rising Competitive Bar Keep Mitchell Kapoor at Hold/Neutral
at www.tipranks.com (Thu, 29-Oct 8:45 AM)
Evommune spotlights Phase 2a atopic dermatitis data: EVO301 hit 55% EASI reduction at Week 12 after just two doses
Market Chameleon (Thu, 1-Oct 8:20 AM)
